NEVRO CORP.
NVRO
NVRO was delisted on the 2nd of April, 2025.
210 hedge funds and large institutions have $4.98B invested in NEVRO CORP. in 2020 Q3 according to their latest regulatory filings, with 34 funds opening new positions, 79 increasing their positions, 77 reducing their positions, and 26 closing their positions.
31% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 26
12% more capital invested
Capital invested by funds: $4.45B → $4.98B (+$530M)
4% more funds holding
Funds holding: 202 → 210 (+8)
3% more repeat investments, than reductions
Existing positions increased: 79 | Existing positions reduced: 77
0% more call options, than puts
Call options by funds: $34.4M | Put options by funds: $34.2M
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$28.6M |
| 2 |
Jennison Associates
New York
|
+$28M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$19.7M |
| 4 |
Millennium Management
New York
|
+$18.3M |
| 5 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$16.9M |
Top Sellers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$68.7M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$44.3M |
| 3 |
HM
HealthCor Management
New York
|
-$43.2M |
| 4 |
Renaissance Technologies
New York
|
-$21.4M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
-$18.1M |
NVRO Hedge Fund Activity: Q3 2020 in Review
210 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in NEVRO CORP. (NVRO) for Q3 2020, worth a combined $4.98B — up 12% from $4.45B a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new NVRO positions and 26 closed out — a net gain of 8 holders — while 79 added to existing stakes and 77 trimmed.
The largest buyer was PFM Health Sciences, adding an estimated $28.6M. The largest seller was Fidelity Investments, cutting an estimated $68.7M.
- 210 institutional investors held NEVRO CORP. (NVRO) as of Q3 2020, up from 202 in Q2 2020.
- Funds reported $4.98B of NEVRO CORP. stock for Q3 2020, up 12% quarter-over-quarter.
- 34 funds opened new NEVRO CORP. positions in Q3 2020 and 26 closed out, a net change of +8 holders.
- The largest NEVRO CORP. buyer in Q3 2020 was PFM Health Sciences, an estimated $28.6M added.
- The largest NEVRO CORP. seller in Q3 2020 was Fidelity Investments, an estimated $68.7M sold.
Based on aggregated 13F filings for Q3 2020.